Related references
Note: Only part of the references are listed.Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis
Marina R. von Essen et al.
BRAIN (2019)
Variability of Spleen and Mesenteric Lymph Node in Control Cynomolgus Monkeys (Macaca fascicularis) from Nonclinical Safety Studies: A Retrospective Assessment
Nancy E. Everds et al.
TOXICOLOGIC PATHOLOGY (2019)
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Stefan Gingele et al.
CELLS (2019)
T Cell Subsets in the Germinal Center: Lessons from the Macaque Model
Monica Vaccari et al.
FRONTIERS IN IMMUNOLOGY (2018)
Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
Darius Haeusler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis
Sorcha Mildiner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Deficiency of the B Cell-Activating Factor Receptor Results in Limited CD169+ Macrophage Function during Viral Infection
Haifeng C. Xu et al.
JOURNAL OF VIROLOGY (2015)
Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery
Susan N. Thomas et al.
CURRENT OPINION IN CHEMICAL ENGINEERING (2015)
Dynamics of B cells in germinal centres
Nilushi S. De Silva et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Arumugam Palanichamy et al.
JOURNAL OF IMMUNOLOGY (2014)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Per S. Sorensen et al.
NEUROLOGY (2014)
Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety
Patricia C. Ryan et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2014)
Induction of Experimental Autoimmune Encephalomyelitis With Recombinant Human Myelin Oligodendrocyte Glycoprotein in Incomplete Freund's Adjuvant in Three Non-human Primate Species
Krista G. Haanstra et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2013)
Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
Cheng-Ping Mao et al.
PLOS ONE (2013)
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Wolfgang F. Richter et al.
AAPS JOURNAL (2012)
Treatment of multiple sclerosis with Anti-CD20 antibodies
Barbara Barun et al.
CLINICAL IMMUNOLOGY (2012)
The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation
Tabitha Turner-Stokes et al.
RHEUMATOLOGY (2011)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Depletion of Functionally Active CD20+T Cells by Rituximab Treatment
Esther Wilk et al.
ARTHRITIS AND RHEUMATISM (2009)
B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans
Klaus Warnatz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2008)
Novel human antibody therapeutics: The age of the Umabs
Sigrid R. Ruuls et al.
Biotechnology Journal (2008)
Species selection considerations for preclinical toxicology studies for biotherapeutics
Jeanine L. Bussiere
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys
Y Vugmeyster et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Depletion of B cells by a humanized Anti-CD20 antibody PRO70769 in Macaca fascicularis
Y Vugmeyster et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys
AF de Vos et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys
C Schröder et al.
TRANSPLANT IMMUNOLOGY (2003)
Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow
ZY Hao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
JCW Edwards et al.
RHEUMATOLOGY (2001)
Share Paper
